Kinaset Therapeutics has scooped up $103 million in a Series B round, five years after emerging with $40 million and a plan to develop an inhaled drug for asthma.
The biotech will …
Read More from Endpoints News
Kinaset rakes in $103M to advance inhaled asthma drug
